Evidence map›Paper›PMID 30413153›Full record

ArticleBMC nephrology2018

Early predictors of one-year mortality in patients over 65 presenting with ANCA-associated renal vasculitis: a retrospective, multicentre study.

Dimitri Titeca-Beauport, Alexis Francois, Thierry Lobbedez, Dominique Guerrot, David Launay, Laurence Vrigneaud, Maité Daroux, Celine Lebas, Boris Bienvenu, Eric Hachulla and 2 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in BMC nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Antimicrobial Prophylaxis in US Medicare Beneficiaries Receiving Immunosuppressants for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2026
    Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Autoimmune-mediated renal disease and hypertension.Clinical science (London, England : 1979) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Dimitri Titeca-BeauportDepartment of Nephrology, Dialysis and Transplantation, Amiens University Hospital, F-80054, Amiens, France. titeca.dimitri@chu-amiens.fr.ORCID 0000-0003-2514-4193
Alexis FrancoisDepartment of Nephrology, Dialysis and Transplantation, Amiens University Hospital, F-80054, Amiens, France.
Thierry LobbedezDepartment of Nephrology, Caen University Hospital, Caen, France.
Dominique GuerrotDepartment of Nephrology, Rouen University Hospital, Rouen, France.
David LaunayUniversity of Lille, U995, Lille, France.
Laurence VrigneaudDepartment of Nephrology and Internal Medicine, Valenciennes General Hospital, Valenciennes, France.
Maité DarouxDepartment of Nephrology, Duchenne Hospital, Boulogne-sur-Mer, France.
Celine LebasDepartment of Nephrology, Calmette Hospital, Lille University Hospital, Lille, France.
Boris BienvenuDepartment of Internal Medicine, Caen, France.
Eric HachullaUniversity of Lille, U995, Lille, France.
Momar DioufClinical Research and Innovation Directorate, Amiens University Hospital, Amiens, France.
Gabriel ChoukrounDepartment of Nephrology, Dialysis and Transplantation, Amiens University Hospital, F-80054, Amiens, France.
Centre Hospitalier Universitaire Amiens-Picardie · FRInserm · FRCentre Hospitalier de Valenciennes · FRHôpital Albert Calmette · FRUniversité de Caen Normandie · FRUniversité d'été de Boulogne-sur-Mer · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe risk of early death is particularly high in patients over the age of 65 presenting with antineutrophil cytoplasmic antibody (ANCA)-associated renal vasculitis. We hypothesized that by combining disease severity markers, a comorbidity index and serious adverse event reports, we would be able to identify early predictors of one-year mortality in this population.

methodsWe performed a multicentre, retrospective study in the nephrology and internal medicine departments of six tertiary hospitals in northern France. A total of 149 patients (median [interquartile range (IQR)] age: 72.7 [68.5-76.8] years) presenting with ANCA-associated vasculitis and renal involvement were included between January 2002 and June 2015. The primary endpoint was the one-year mortality rate.

resultsRenal function was severely impaired at presentation (median [IQR] peak serum creatinine (SCr): 337 [211-522] μmol/l), and 45 patients required dialysis. The Five-Factor Score (FFS, scored as + 1 point for each poor prognostic factor (age > 65 years, cardiac symptoms, gastrointestinal involvement, SCr ≥150 μmol/L, and the absence of ear, nose, and throat involvement)) was ≥3 in 120 cases. The one-year mortality rate was 19.5%. Most of the deaths occurred before month 6, and most of these were related to severe infections. In a univariate analysis, age, a high comorbidity index, a performance status of 3 or 4, a lack of co-trimoxazole prophylaxis, early severe infection, and disease activity parameters (such as the albumin level, haemoglobin level, peak SCr level, dialysis status, and high FFS) were significantly associated with one-year mortality. In a multivariable analysis, the best predictors were a high FFS (relative risk (RR) [95% confidence interval (CI)] = 2.57 [1.30-5.09]; p = 0.006) and the occurrence of a severe infection during the first month (RR [95%CI] = 2.74 [1.27-5.92]; p = 0.01).

conclusionsWhen considering various disease severity markers in over-65 patients with ANCA-associated renal vasculitis, we found that an early, severe infection (which occurred in about a quarter of the patients) is a strong predictor of one-year mortality. A reduction in immunosuppression, the early detection of infections, and co-trimoxazole prophylaxis might help to reduce mortality in this population.

Indexed as

AgedAged, 80 and overAge FactorsAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisFemaleFollow-Up StudiesFranceHumansMaleMortalityPredictive Value of TestsRetrospective StudiesANCAElderlyGlomerulonephritisInfectionMortality

Identifiers

PMID30413153
PMCPMC6234782
OpenAlexW2900385992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.